International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Advances in Asthma Management: Integrating Biologics, Personalized Medicine, and Lessons from the COVID-19 Era

Vaibhav Ramdas Jadhav[1], Akanksha Madhukar Purkar[2], Nikita Santosh Dukale[3], Rohit Balkrushna Sonawane[4], Kunal Sunil Niphade[5]

[1,2,3,4]Final Year B.Pharmacy, Swami Institute Of Pharmacy, Abhona, Nashik
[5]Third Year B.Pharmacy, Swami Institute Of Pharmacy, Abhona, Nashik

Abstract
Asthma remains a global health challenge, affecting over 300 million individuals. While inhaled corticosteroids (ICS) and short-acting β_2-agonists (SABAs) form the cornerstone of therapy, emerging biologic agents and personalized approaches are revolutionizing care. This review explores recent advancements in biologic therapies targeting specific inflammatory pathways, the role of biomarkers in precision medicine, and the evolving impact of COVID-19 on asthma management. We also evaluate barriers to control, such as poor adherence and phenotypic heterogeneity, and propose strategies to integrate novel therapies into clinical practice. By synthesizing evidence from key trials and epidemiological studies, this work underscores the importance of tailored treatment algorithms to reduce morbidity and mortality.

Introduction
Asthma is a chronic respiratory disorder characterized by reversible airflow limitation, inflammation, and airway hyperresponsiveness. According to the Global Initiative for Asthma (GINA), over 339 million individuals worldwide suffer from asthma, making it one of the most prevalent non-communicable diseases.
Despite advancements in treatment, asthma remains a major cause of morbidity and healthcare costs, with exacerbations leading to millions of emergency department visits annually.
The economic burden is immense, with direct costs including hospitalization and medication expenses, and indirect costs arising from lost productivity and disability.
Asthma care has evolved significantly over the past few decades. From non-specific bronchodilators to highly targeted biologics, the field has transitioned towards precision medicine.
Personalized approaches, driven by biomarkers, genetics, and inflammatory phenotypes, are improving treatment efficacy.
However, disparities in asthma care persist, particularly in low-income countries where access to advanced therapies is limited.
This review explores recent advancements in biologic therapies, precision medicine, and lessons from the COVID-19 pandemic that have influenced asthma management.

Pathophysiology Updates
Asthma pathophysiology involves dynamic interactions between genetic predisposition, environmental triggers, and immune dysregulation. Key mechanisms include:
1. Type 2 Inflammation: Driven by IL-4, IL-5, and IL-13, leading to eosinophil recruitment and IgE production.
2. Non-Type 2 Pathways: Neutrophilic or paucigranulocytic inflammation mediated by IL-17 and TNF-α.
3. Airway Remodeling: Persistent inflammation results in subepithelial fibrosis and smooth muscle hypertrophy, contributing to irreversible obstruction.

Epigenetics and Environmental Influences:
Environmental pollutants, viral infections, and maternal smoking have been linked to asthma through epigenetic modifications.
The gut-lung axis is an emerging area of interest, with dysbiosis in gut microbiota contributing to immune dysregulation in asthma.
Understanding these mechanisms has led to the development of targeted biologics and biomarker-driven therapies.
Precision medicine is revolutionizing asthma treatment by leveraging biomarkers, genetic profiling, and AI-driven models.

Recent Advancements in Biologic Therapies
Biologics have transformed severe asthma management by targeting specific inflammatory mediators (Table 1).

Table 1: Biologic Therapies for Severe Asthma*

Target	Drug	Mechanism	Key trials
IgE	Omalizumab	Binds IgE, preventing mast cell degranulation	INNOVATE (2005) [1]
IL-5/IL-5R	Mepolizumab Benralizumab	Depletes eosinophils	| MENSA (2014) [2], SIROCCO (2016) [3]
IL-4Rα	Dupilumab	Blocks;IL-4/IL-13 signaling	QUEST (2018) [4]
TSLP	Tezepelumab	Inhibits epithelial alarmin TSLP	NAVIGATOR (2021) [5]

Key Insights:
Tezepelumab: First biologic effective in both Type 2 and non-Type 2 asthma, reducing exacerbations by 56% [5].
Dupilumab: Improves lung function in moderate-to-severe asthma with comorbid atopic dermatitis [4].
Real-World Efficacy: Biologics reduce exacerbations by 40–60% and oral corticosteroid use by 50% [6].

Personalized Medicine in Asthma

Precision medicine leverages biomarkers to tailor therapies:

1. Biomarker-Guided Therapy:

Blood Eosinophils: >300 cells/μL predicts response to anti-IL-5 agents [7].

FeNO: >50 ppb indicates ICS responsiveness and guides anti-IgE use [8].

Periostin: Serum levels correlate with Th2 inflammation and omalizumab efficacy [9].

2. Genetic Profiling:

ADRB2 Polymorphisms: Arg/Arg genotype at position 16 reduces β_2-agonist response [10].

Genome-wide association studies (GWAS) are identifying novel susceptibility genes for asthma phenotypes

RTh2 Antagonists: Under investigation for prostaglandin-driven asthma [11].

3. Treatable Traits Approach:

Focuses on modifiable characteristics (e.g., eosinophilia, smoking) rather than diagnostic labels [12].

4. AI and Machine Learning in Asthma Care:

AI-driven decision-support tools analyze electronic health records and biomarker data to predict treatment response.

Digital health technologies, such as smart inhalers, enhance adherence monitoring and early exacerbation detection.

Impact of COVID-19 on Asthma Management

The pandemic reshaped asthma care through:

- **Risk Stratification:**
  - Early fears linked ICS and biologics to COVID-19 susceptibility, but subsequent studies found no increased risk in well-controlled asthma [13].
  - Poorly controlled asthma (FEV_1 <60%) correlated with severe COVID-19 outcomes [14].
- **Telemedicine Adoption:**
  - Virtual visits improved adherence monitoring and reduced exacerbations in 30% of patients [15].
- **Exacerbation Trends:**
  - Global reductions in asthma hospitalizations (40–50%) during lockdowns, attributed to reduced air pollution and viral exposure [16].
- **Vaccination Guidance:**
  - GINA recommends asthma patients prioritize COVID-19 vaccination, with no contraindications for biologics [17].

Barriers to Asthma Control

Cost and Access to Biologics:

- Biologic therapies cost between $25,000 and $40,000 per year, limiting accessibility.
- Healthcare policies must address cost-effectiveness and reimbursement models. [18]

Inhaler Technique and Adherence:

- Studies show 40-60% of asthma patients misuse inhalers, reducing treatment efficacy.
- Educational interventions and smart inhalers improve adherence rates.

Health Disparities:

- Socioeconomic factors, race, and geographic disparities contribute to unequal asthma outcomes.

- Policy efforts must focus on reducing disparities through targeted public health interventions.
- **Phenotypic Complexity**: Non-Type 2 asthma lacks targeted therapies.

Future Directions

1. **Novel Biologics**: Anti-IL-33 (itepekimab) and anti-TSLP (tezepelumab) in Phase III trials [20].
2. **Digital Tools**: Smart inhalers (e.g., Propeller Health) improve adherence via real-time tracking [21].
3. **Climate Change**: Mitigating air pollution and allergens may reduce exacerbations [22].

Conclusion

The asthma treatment landscape is evolving rapidly, driven by biologics, personalized approaches, and pandemic-driven innovations. Integrating biomarker-guided strategies and addressing socioeconomic disparities are critical to achieving global control. Future research must prioritize cost-effective biologics, non-Type 2 therapies, and climate-resilient care models.

References

1. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma. J Allergy Clin Immunol. 2005;116(5):1086-1092.
2. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-1207.
3. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma: SIROCCO trial. Lancet. 2016;388(10056):2115-2127.
4. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy in uncontrolled moderate-to-severe asthma. N Engl J Med.2018;378(26):2486-2496.
5. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med.2021;385(20):1809-1819.
6. Agache I, Beltran J, Akdis C, et al. Real-world effectiveness of biologics in severe asthma. Allergy. 2022;77(2):484-497.
7. Buhl R, Humbert M, Bjermer L, et al. Targeting eosinophils with mepolizumab in severe asthma. Eur Respir J. 2017;50(3):1700036.
8. Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma. Am J Respir Crit Care Med. 2013;187(8):804-811.
9. Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation. J Allergy Clin Immunol.2012;130(3):647-654.
10. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified trials. Lancet. 2004;364(9444):1505-1512.
11. Singh D, Beeh KM, Colgan B, et al. Effect of CRTh2 antagonism on airway inflammation and allergen challenge. Respir Res.2022;23(1):45.
12. Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410-419.
13. Jackson DJ, Busse WW, Bacharier LB, et al. Association of respiratory allergy, asthma, and COVID-19 outcomes. J Allergy Clin Immunol. 2021;147(3):790-798.
14. Sunjaya AP, Allida SM, Di Tanna GL, et al. Asthma and COVID-19 risk: a systematic review. Eur Respir J. 2022;59(3):2101209.

15. Portnoy JM, Waller M, De Lurgio S, et al. Telemedicine for asthma care during COVID-19. Ann Allergy Asthma Immunol.2021;126(5):524-530.
16. Davies GA, Alsallakh MA, Sivakumaran S, et al. Impact of COVID-19 lockdown on asthma exacerbations. Thorax. 2021;76(9):919-921.
17. Global Initiative for Asthma (GINA). COVID-19: GINA answers to frequently asked questions. 2023. Available from: https://ginasthma.org.
18. Reddel HK, Bacharier LB, Bateman ED, et al. Global asthma mortality and morbidity in low-income countries. Lancet Respir Med. 2022;10(1):69-81.
19. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in asthma. Respir Med.2020;163:105893.
20. Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: Clinical impact and management. Respirology. 2017;22(4):651-661.
21. Merchant RK, Inamdar R, Quade RC. Effectiveness of a digital health intervention for asthma. J Allergy Clin Immunol Pract. 2021;9(2):857-865.
22. D'Amato G, Chong-Neto HJ, Monge Ortega OP, et al. The effects of climate change on respiratory allergy and asthma. Allergy.2020;75(9):2218-2228.